# 蘇州瑞博生命科學有限公司受邀於3月19日在奧地利維也納舉行的RNA Leaders Europe會議發表演講。

*biotech · news · 2026-03-20 · The Manila Times*

## Key points

- Ribo的RiboPepSTAR™技術實現精準將siRNA遞送至肝臟以外的器官。
- 臨床前研究顯示RiboPepSTAR™在腎臟細胞中可達到高達80%的目標基因敲低效果。
- 心臟定向siRNA偶聯物展現持續且心臟特異性的基因敲低，且副作用極小。
- 在非人靈長類(NHP)中，Ribo的遞送系統選擇性地在脂肪組織中實現96%的基因敲低。
- Ribo的多目標siRNA平台能同時高效沉默兩個或以上基因。

SUZHOU, China and MÖLNDAL, Sweden, March 20, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. ("Ribo" or "the Company", Hong Kong Stock Exchange code: 6938) had been invited to give a speech at the RNA Leaders Europe Conference in Vienna, Austria on March 19th, one of the top oligonucleotide conferences. Following the success of RiboGalSTAR™, which has supported seven clinical programs and major global partnerships valued over USD 6 billion, Ribo is now advancing its extra hepatic and multi-target platforms. The proprietary RiboPepSTAR™ technology enables precise siRNA delivery to key organs beyond the liver, with promising preclinical data across several tissues. Kidney targeting Using RiboPepSTAR™, preclinical studies demonstrate selective uptake in proximal tubular cells across models, and up to 80% target gene knockdown (KD) has been achieved, from rodents to NHPs. Physiological proof of concept was further validated in several disease models, such as type 2 diabetes model, showing robust kidney specific target-related biomarker reduction. Ribo's first kidney-targeted drug has entered IND-enabling phase. Cardiac targeting A cardiac targeting conjugate resulted in sustained knockdown in heart using a mouse model. Minimal effects were observed in muscle and negligible activity in liver and kidney, confirming strong cardiac specificity. Adipose tissue targeting In NHPs, current delivery enabled potent and selective adipose targeting with 96% knockdown. Together, these results underscore RiboPepSTAR™'s potential to unlock siRNA-based therapies for renal, cardiac and metabolic diseases. In parallel, Ribo is advancing its multi target siRNA platform, enabling a single molecule to silence two or more genes simultaneously. Ribo's dual target siRNAs achieve knockdown levels comparable to single target molecules, enabling synergistic pathway modulation and enhanced therapeutic benefit with a single therapeutic entity. Ribo's proprietary extra hepatic and multi targeting platforms open the door to best-in-class therapies across a broad range of disease areas - fully aligned with Ribo's commitment to delivering next generation siRNA medicines to patients worldwide.

**Companies:** Suzhou Ribo Life Science Co., Ltd.
**Countries:** China, Sweden, Austria

[Read the full story on The Manila Times](https://www.manilatimes.net/2026/03/20/tmt-newswire/pr-newswire/ribo-expands-beyond-the-liver-with-ribopepstar-enabling-targeted-sirna-delivery-to-multiple-organs/2304265)

---

Canonical: https://newsio.io/zh-TW/n/6e54daf5-fd6c-4408-a75f-cc162bf38e6d/319rna-leaders-europeriboind
Summarized by Newsio from The Manila Times. https://newsio.io/how-it-works